Immunosuppressive
medicines are used to weaken or suppress the immune system of the body.
Immunosuppressive medications are used to treat autoimmune illnesses such as
rheumatoid arthritis, psoriasis, multiple sclerosis, and others. Anti-rejection
medicines are immunosuppressive drugs used in organ transplantation procedures.
When a person has an organ transplant, the body recognises the donated organ as
a foreign mass, prompting the immune system to attack it, resulting in organ
rejection. Immunosuppressive medicines are used to reduce the immune response
to foreign organs in order to avert such occurrences. Blood tests are required
on a regular basis to check the drug's effects on the body. Immunosuppressive
medications are extremely potent and can result in side effects such as kidney
disease, high blood pressure, and liver disease. Effectiveness of
immunosuppressant drugs as an anti-rejection compound in organ transplantation
procedure to propel the market growth
The immunosuppressant
medications market is growing due to an increase in the number of cases
of organ failure and the need for organ transplantation. According to the
ONT-WHO Global Observatory on Donation and Transplantation, about 119,873
organs were transplanted globally in 2014, an increase of 1.8 percent from
2013. The market for immunosuppressant medications is growing due to
advancements in tissue engineering and transplantation methods. One of the
major factors driving the growth of the immunosuppressant medicines market is
the rise in the number of autoimmune illnesses. According to the American
Autoimmune Related Disease Association (AARDA), 50 million persons in the
United States suffered from autoimmune illnesses in 2016. Anti-inflammatories
medicines have been shown to be beneficial in the treatment of autoimmune
illnesses.
However, the
ambiguity of immunosuppressant medications' action on complex organ
transplantations and a lack of understanding about these drugs among patients
are two main limitations that are projected to stifle the market's expansion.
Over the forecast period, advanced therapies such as stem cell therapy, which
is utilised as a substitute for organ transplantation, are expected to restrain
the growth of the immunosuppressant medicines market.
Key players focus on the approval and
commercialization of their drugs
Novartis AG,
Accord Healthcare, AstellaPharma, Watson Pharmaceuticals, Genzyme Co.,
Bristol-Myers Squibb, Mylan Laboratories Inc., GlaxoSmithKline Plc, and Roche
are among the major competitors in the immunosuppressant pharmaceuticals
market. The market players have recognised commercialization of their products
as a major strategy. They are involved in the approval and clearance of new
medications. Nulojix (belatacept), for example, was approved by the Food and
Drug Administration (FDA) in 2011. Belatacept would be superior than other
immunosuppressant medications in organ transplant, according to a study
completed in 2015. Bristol-Myers Squibb is involved in the commercialization of
this drug.
Comments
Post a Comment